SynKIR-310 for Relapsed/Refractory B-NHL
Public ClinicalTrials.gov record NCT06544265. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study of SynKIR-310, Autologous T Cells Transduced With CD19 KIR-CAR, in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.
Study identification
- NCT ID
- NCT06544265
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 36 participants
Conditions and interventions
Conditions
- B Cell Lymphoma
- NHL, Adult
- Mantle Cell Lymphoma
- Relapsed Non-Hodgkin Lymphoma
- Refractory Non-Hodgkin Lymphoma
- Aggressive B-Cell Non-Hodgkin Lymphoma
- Indolent B-Cell Non-Hodgkin Lymphoma
- Follicular Lymphoma
- Marginal Zone Lymphoma
- DLBCL - Diffuse Large B Cell Lymphoma
- HGBL With MYC and BCL2 and/or BCL6 Rearrangements
- High-grade B-cell Lymphoma
- Diffuse Large B Cell Lymphoma
- Large B-cell Lymphoma
- T-Cell/Histiocyte Rich Lymphoma
- Non-hodgkin Lymphoma,B Cell
- Primary Mediastinal Large B-cell Lymphoma (PMBCL)
- Epstein-Barr Virus Positive DLBCL, Nos
- Follicular Lymphoma Grade 3B
- DLBCL (Diffuse Large B-Cell Lymphoma) Associated With Chronic Inflammation
- High Grade B-Cell Lymphoma, Not Otherwise Specified
- Follicular Lymphoma Grade 3
- Marginal Zone Splenic Lymphoma
- DLBCL
- Waldenstrom Macroglobulinemia
- Waldenstrom Macroglobulinaemia
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2024
- Primary completion
- Aug 31, 2028
- Completion
- Nov 30, 2028
- Last update posted
- Apr 13, 2026
2024 – 2028
United States locations
- U.S. sites
- 5
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Colorado Blood Cancer Institute, part of Sarah Cannon Cancer Institute | Denver | Colorado | 80218 | Recruiting |
| Winship Cancer Institute of Emory University | Atlanta | Georgia | 30322 | Recruiting |
| The University of Kansas Cancer Center | Fairway | Kansas | 66205 | Recruiting |
| Rutgers Cancer Institute | New Brunswick | New Jersey | 08902 | Recruiting |
| Abramson Cancer Center of the University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06544265, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 13, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06544265 live on ClinicalTrials.gov.